There are over 80 different sub-types of lymphoma, which are treated according to different protocols with very high costs.
Identifying the correct sub-type is a challenging, time-consuming task, requiring the pathologist to combine information from many (>15) different biomarkers.
Information on the co-localization of markers on the same cells is missing as standard-of-care includes staining multiple slides each with a single marker.